ARTICLE | Finance
Extra crisp
Why Versant Ventures thinks there's room for another CRISPR-Cas9 play
April 28, 2014 7:00 AM UTC
Versant Ventures is adding another horse to the CRISPR-Cas9 therapeutics race with last week's $25 million series A round for CRISPR Therapeutics.
Versant was the sole investor in CRISPR, which is developing gene editing therapies for serious genetic diseases...